CDK12 and triple-negative breast carcinoma: In models of triple-negative breast cancer (TNBC) which is an invasive breast carcinoma subgroup, dinaciclib as a CDK12 inhibitor cuts down the expression of HR gene in BCRA wild-type TNBC cells.